Clinical and radiological results of thoracic and lumbar fracture and dislocation treated with posterior transforaminal decompression and interbody fusion / 中国骨伤

OBJECTIVE@#To evaluate the clinical and radiological results of patients with thoracic and lumbar fracture and dislocation treated by posterior transforaminal decompression and interbody fusion.@*METHODS@#From June 2010 to June 2017, posterior transforaminal decompression, interbody fusion combined with pedicle screw fixation were performed in 21 patients with thoracic and lumbar fracture and dislocation. Their clinical and radiological data were collected and retrospectively analyzed, including 15 males and 6 females, aged from 25 to 58 years with an average of 45 years old. According to the criterion of American Spinal Injury(ASIA), preoperative neurological function was graded A in 3 cases, B in 7 cases, C in 6 cases, D in 4 cases and E in 1 case. Operative time and intraoperative blood loss and correlative complications were recorded. And VAS score, ODI and Cobb angle were evaluated before and after surgery. The improvement of neurological function was also analyzed at the final follow-up. Intervertebral bony fusion was observed during the follow-up by CT three-dimensional reconstruction.@*RESULTS@#The operative time was 150 to 240 min with an average of (192±47) min. The intraoperative blood loss was 380 to 750 ml with an average of(603±120) ml. Dura sac tearing and cerebral fluid leakage occurred in 3 cases and were repaired during operation; superficial wound infection occurred in 1 case, and got healing after dressing change. The postoperative follow-up duration was 24 to 45 months with an average of(37.0±9.5) months. VAS score was improved from preoperative 8.9±0.4 to immediately postoperative 4.2±1.3(<0.05). At the final follow-up, VAS score decreased further to 3.6±0.8. ODI was decreased from preoperative (95.30±3.52)% to (32.51±6.30)% at the final follow-up (<0.05). Cobb angle was corrected from preoperative (21.2±8.8)° to immediately postoperative(2.3±3.1)° (<0.05). At the final follow-up, Cobb angle was (3.2±2.5)°, showing no significant difference with immediately postoperative value. The neurological function was grade A in 3 cases, B in 3 cases, C in 5 cases, D in 6 cases and E in 4 cases at the final follow-up. All the patients got solid intervertebral bone fusion in 8 to 13 months after operation, with an average fusion time of (10.3±2.5) months.@*CONCLUSIONS@#For the patients with thoracic and lumbar fracture and dislocation mainly involving intervertebral disc and endplate plane, posterior transforaminal decompression and interbody fusion not only is less invasive, but also can effectively reconstruct spinal three column and obtain good biomechanical stability. And, it is beneficial for the good recovery of neurological function.

Clinical observation of capecitabine monotherapy or combination regimen in the treatment of advanced breast cancer / 中国生化药物杂志

Objective To explore the clinical effect and safety of patients with advanced breast cancer with capecitabine and gemcitabine combined with capecitabine treatment scheme. Methods 82 cases of patients with advanced breast cancer received treatment in our hospital from February 2014 to March 2016 were randomly selected and were randomly divided into control group and study group, 41 cases in each group.The control group using capecitabine monotherapy, the study group used capecitabine combined with docetaxel treatment. The therapeutic effects, safety and adverse reactions of the two groups were compared. Results The effective rate of treatment in the study group was 56.48 %, significantly better than that in the control group(34.28 %), the difference was statistically significant, The incidence of complications after treatment in the control group was 40.22 %, significantly higher than that in the study group (18.04 %), and the difference was statistically significant (P<0.05). Conclusion Capecitabine combined with docetaxel in the treatment of advanced breast cancer has good effect and low incidence of adverse reactions. It is worthy of recommendation and Application.

Clinical observation of capecitabine monotherapy or combination regimen in the treatment of advanced breast cancer / 中国生化药物杂志

Objective To explore the clinical effect and safety of patients with advanced breast cancer with capecitabine and gemcitabine combined with capecitabine treatment scheme. Methods 82 cases of patients with advanced breast cancer received treatment in our hospital from February 2014 to March 2016 were randomly selected and were randomly divided into control group and study group, 41 cases in each group.The control group using capecitabine monotherapy, the study group used capecitabine combined with docetaxel treatment. The therapeutic effects, safety and adverse reactions of the two groups were compared. Results The effective rate of treatment in the study group was 56.48 %, significantly better than that in the control group(34.28 %), the difference was statistically significant, The incidence of complications after treatment in the control group was 40.22 %, significantly higher than that in the study group (18.04 %), and the difference was statistically significant (P<0.05). Conclusion Capecitabine combined with docetaxel in the treatment of advanced breast cancer has good effect and low incidence of adverse reactions. It is worthy of recommendation and Application.